CN112870333A - Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof - Google Patents
Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof Download PDFInfo
- Publication number
- CN112870333A CN112870333A CN202110158512.0A CN202110158512A CN112870333A CN 112870333 A CN112870333 A CN 112870333A CN 202110158512 A CN202110158512 A CN 202110158512A CN 112870333 A CN112870333 A CN 112870333A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- hair
- mixture
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 74
- 230000003779 hair growth Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 230000001737 promoting effect Effects 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 143
- 210000004209 hair Anatomy 0.000 claims abstract description 133
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 44
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 22
- 229960002685 biotin Drugs 0.000 claims abstract description 22
- 235000020958 biotin Nutrition 0.000 claims abstract description 22
- 239000011616 biotin Substances 0.000 claims abstract description 22
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 21
- 244000090896 Nigella sativa Species 0.000 claims abstract description 21
- 235000016698 Nigella sativa Nutrition 0.000 claims abstract description 21
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 239000001711 nigella sativa Substances 0.000 claims abstract description 20
- 244000136948 Ocimum sanctum Species 0.000 claims abstract description 19
- 235000004072 Ocimum sanctum Nutrition 0.000 claims abstract description 19
- 244000286838 Eclipta prostrata Species 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 13
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 11
- 239000000341 volatile oil Substances 0.000 claims abstract description 10
- 239000002453 shampoo Substances 0.000 claims abstract description 8
- 210000000720 eyelash Anatomy 0.000 claims abstract description 7
- 210000004709 eyebrow Anatomy 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 47
- 208000024963 hair loss Diseases 0.000 claims description 30
- 230000003676 hair loss Effects 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 20
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 239000003921 oil Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000003752 improving hair Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 230000002335 preservative effect Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 9
- 229940101267 panthenol Drugs 0.000 claims description 9
- 235000020957 pantothenol Nutrition 0.000 claims description 9
- 239000011619 pantothenol Substances 0.000 claims description 9
- 241001621841 Alopecurus myosuroides Species 0.000 claims description 8
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 8
- NFPWMUOQSJXGGZ-ZZTWKDBPSA-N N-[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O NFPWMUOQSJXGGZ-ZZTWKDBPSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 claims description 6
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 6
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 6
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 5
- 230000003658 preventing hair loss Effects 0.000 claims description 5
- 229920000289 Polyquaternium Polymers 0.000 claims description 4
- 229940048109 sodium methyl cocoyl taurate Drugs 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 150000003863 ammonium salts Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940104256 sodium taurate Drugs 0.000 claims description 2
- GWLWWNLFFNJPDP-UHFFFAOYSA-M sodium;2-aminoethanesulfonate Chemical compound [Na+].NCCS([O-])(=O)=O GWLWWNLFFNJPDP-UHFFFAOYSA-M 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000012010 growth Effects 0.000 abstract description 10
- 244000061520 Angelica archangelica Species 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 230000008719 thickening Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 37
- 210000003780 hair follicle Anatomy 0.000 description 27
- 210000003734 kidney Anatomy 0.000 description 23
- 210000004761 scalp Anatomy 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 238000011160 research Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 210000003837 chick embryo Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- -1 myristoyl pentapeptide-1 Chemical compound 0.000 description 7
- 235000021286 stilbenes Nutrition 0.000 description 7
- 208000001840 Dandruff Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 240000002924 Platycladus orientalis Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 241001518085 Nigella glandulifera Species 0.000 description 3
- 240000001341 Reynoutria japonica Species 0.000 description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000003648 hair appearance Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 2
- WCKVVODUWGBPQV-SOADLSRISA-N (2s)-2-[[(2s)-2-[[2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]acetyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-6-aminohexanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)CNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1)C1=CN=CN1 WCKVVODUWGBPQV-SOADLSRISA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 241000218691 Cupressaceae Species 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 201000002996 androgenic alopecia Diseases 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940117901 biotinoyl tripeptide-1 Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000003646 hair health Effects 0.000 description 2
- 230000003660 hair regeneration Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- LMNZTLDVJIUSHT-UHFFFAOYSA-N phosmet Chemical compound C1=CC=C2C(=O)N(CSP(=S)(OC)OC)C(=O)C2=C1 LMNZTLDVJIUSHT-UHFFFAOYSA-N 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000002602 strong irritant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- YCNCRLKXSLARFT-UHFFFAOYSA-N 2-hydroxy-2-methyl-n-[4-nitro-3-(trifluoromethyl)phenyl]-3-[(2,2,2-trifluoroacetyl)amino]propanamide Chemical compound FC(F)(F)C(=O)NCC(O)(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YCNCRLKXSLARFT-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- ARBYGDBJECGMGA-UHFFFAOYSA-N 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)N(CCCCO)C(=O)N1C1=CC=C(C#N)C(C(F)(F)F)=C1 ARBYGDBJECGMGA-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000271309 Aquilaria crassna Species 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000000774 Cunila origanoides Species 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010048462 Growth of eyelashes Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000003774 positive effect on hair Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000012190 sympathetic paraganglioma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 description 1
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition for improving alopecia and growing hair of human, a preparation and a preparation method thereof, wherein the composition comprises the following components: 10.05-1 parts of biotin tripeptide, 170.05-1 parts of myristoyl pentapeptide, 0.01-1 parts of glossy privet fruit extract, 0.01-1 parts of eclipta extract, 0.01-1 parts of cortex dictamni extract, 0.01-1 parts of radix sophorae flavescentis extract, 0.01-1 parts of cortex mori extract, 0.01-1 parts of cacumen biotae extract, 0.01-1 parts of polygonum multiflorum extract, 0.01-1 parts of angelica extract, 0.01-1 parts of agilawood extract, 0.01-1 parts of nigella sativa seed extract and 0.01-1 parts of holy basil extract. The composition is a Chinese medicinal compound and biological polypeptide composition, can improve alopecia and promote blackening and thickening of hair, and can be used in hair growth products for preventing alopecia, including shampoo, hair conditioner, hair care essential oil, hair mask, eyebrow and eyelash growth promoting liquid, etc.
Description
Technical Field
The invention relates to the technical field of scalp care, in particular to a composition and a preparation for improving alopecia and growing hair of people, and a preparation method and application thereof.
Background
The hair has not only the function of beauty but also the biological function and the physiological function for people, and can influence the psychology and the social interaction of people. With the rapid development of social economy and the accelerated pace of life, the phenomenon of alopecia caused by various reasons is increasing. Alopecia and baldness are common skin diseases clinically at home and abroad at present, according to health indexes issued by relevant departments of China, the alopecia incidence rate in adult people in China is up to 40%, and the onset age tends to be younger. Studies have shown that patients with alopecia have both sleep quality and emotional problems. People are increasingly demanding hair care products. Hair care products have become the fastest growing consumer goods in recent years, and the development of safe and effective external products for treating alopecia has been a research hotspot for a long time.
Alopecia may be caused by nerve damage, insufficient nutrition supply, genetics, endocrine, mental and medicinal factors, and the like. Clinically, the alopecia is divided into two types, the most common alopecia type is androgenetic alopecia (also called seborrheic alopecia) and alopecia areata. In addition, the alopecia caused by alopecia includes hereditary alopecia, nutritional disorder alopecia, chemotherapy alopecia, senile alopecia, alopecia after illness, etc. Statistics shows that more than 80 percent of alopecia patients belong to seborrheic alopecia clinically. Seborrheic alopecia occurs regardless of gender, but occurs at a higher rate in men. Studies have long shown that seborrheic alopecia occurs in 50% of men aged 50 and the incidence may rise to 70% with age. At present, the pathogenesis of seborrheic alopecia is well-known to be that after androgen is combined with a receptor to generate a series of reactions, cell proliferation and differentiation are regulated, cell processes are triggered, hair enters a resting period prematurely, hair follicles are miniaturized, and accordingly alopecia is caused.
The scientists believe that seborrheic alopecia is an androgen-dependent genetic disease, the pathogenesis of the seborrheic alopecia is not clear, at present, the seborrheic alopecia is directly related to factors such as abnormal change of androgen metabolism in circulating blood, increase of 5 alpha-reductase level of hair follicle tissues and the like, and is a result of multi-factor synergistic action, and in recent years, the following two methods are mainly adopted for foreign treatment: anti-androgen methods, such as 5 α -reductase inhibitors: finasteride, Dutasteride, W09704002; epristeride; androgen receptor competition blockers: cimetidine, RU58841, spironolactone, flurodil (fluridil); anti-androgenic drugs: dexamethasone, flutamide; estrogens: an oral contraceptive; ② biological reaction modification factors: for example, minoxidil, cyclosporine A, tretinoin and other drugs commonly used in clinic, such as finasteride, minoxidil and other drugs can promote hair regeneration, but the curative effect is difficult to maintain due to continuous alopecia after drug withdrawal, the treatment time is long, and the side effect is very obvious, for example, finasteride can cause adverse reactions such as mild liver dysfunction, sexual dysfunction, moderate and severe depression, emotional disorder, sleep disorder, abnormal eating habits and the like. Minoxidil can cause certain irritation to scalp, and the main adverse reaction is hirsutism.
Traditional Chinese medicine considers that hair health is related to liver, kidney, spleen, qi and blood. The hair is not nourished because the hair is not full of blood, which can cause alopecia. The hair follicle is a sac-like tissue surrounding the root of a hair, and the main function is to form hair tissue. That is, hair is supplied with nutrients necessary for growth by blood, and if the blood supply around the hair follicles on the scalp is insufficient, hair loss is caused. The kidney governs bones and produces marrow, which is prosperous to hair, and the hair will grow vigorously, have moist and lustrous hair quality and be black and dark when the kidney qi is enough, and the hair is not easy to fall off. On the contrary, the deficiency of kidney qi can make hair grow slowly, the hair quality worsen, the color is grey, and the hair is easy to fall off. Alopecia is mainly classified into liver and kidney deficiency, spleen deficiency with dampness, blood deficiency, wind with blood dryness, liver depression with blood stasis and other types according to different pathogenesis in traditional Chinese medicine.
The traditional Chinese medicine treats diseases, gives full consideration to holism and treats based on syndrome differentiation. For the treatment of alopecia, different treatment methods are adopted according to different causes. At present, the traditional Chinese medicine is mostly prepared by adopting a compound method for treating the alopecia, and the traditional Chinese medicine theory is taken as guidance, and the hair loss is treated by adopting the forms of oral administration, external application or internal and external combined treatment, and the like, so that the traditional Chinese medicine has better curative effect. The traditional Chinese medicine is externally used for treating alopecia, and is mainly used for improving local blood circulation and supplementing hair nutrition.
In addition, the biological peptide components developed in recent years, such as biological peptide 3 peptide-1 (biotinyl polypeptide-1) and Myristoyl pentapeptide-17 (Myristoyl polypeptide-1), have the effects of promoting scalp microcirculation, inhibiting the activity of 5 alpha-reductase and remarkably activating keratin. The market of the external cosmetic product prepared by combining the traditional Chinese medicine compound and the biological peptide is blank at present.
Disclosure of Invention
In order to overcome the defects of the prior art, one of the purposes of the invention is to provide a composition for improving the alopecia and growing hair of people, which is a composition of a traditional Chinese medicine compound and biological polypeptide, can effectively improve the alopecia and promote the hair to become black and dense, is directly acted on an affected part when being externally used, is high in safety and quick in effect, and has a good effect of improving the alopecia by clinical tests.
The second purpose of the invention is to provide a preparation for improving alopecia and growing hair of people, which can obviously reduce the number of alopecia of patients with seborrheic alopecia and improve clinical symptoms such as hair oil, dandruff, scalp itch and the like.
The invention also aims to provide a preparation method of the preparation for improving the alopecia and the hair growth of the human, which has simple and convenient process and is beneficial to industrial production.
The fourth purpose of the invention is to apply the composition for improving human hair loss and growing hair to a hair loss prevention and growing product, wherein the hair loss prevention and growing product comprises shampoo, hair conditioner, hair care essential oil, hair mask (hairdressing gel), eyebrow growing liquid and eyelash growing liquid.
One of the purposes of the invention is realized by adopting the following technical scheme:
a composition for improving alopecia and promoting hair growth of a human comprises the following components in parts by weight: 10.05-1 parts of biotin tripeptide, 170.05-1 parts of myristoyl pentapeptide, 0.01-1 parts of glossy privet fruit extract, 0.01-1 parts of eclipta extract, 0.01-1 parts of cortex dictamni extract, 0.01-1 parts of radix sophorae flavescentis extract, 0.01-1 parts of cortex mori extract, 0.01-1 parts of cacumen biotae extract, 0.01-1 parts of polygonum multiflorum extract, 0.01-1 parts of angelica extract, 0.01-1 parts of agilawood extract, 0.01-1 parts of nigella sativa seed extract and 0.01-1 parts of holy basil extract.
Further, the coating comprises the following components in parts by weight: 10.05-0.8 part of biotin tripeptide, 170.05-0.8 part of myristoyl pentapeptide, 0.01-0.5 part of glossy privet fruit extract, 0.01-0.5 part of eclipta extract, 0.01-0.5 part of cortex dictamni extract, 0.01-0.5 part of radix sophorae flavescentis extract, 0.01-0.5 part of cortex mori extract, 0.01-0.5 part of cacumen biotae extract, 0.01-0.5 part of polygonum multiflorum extract, 0.01-0.5 part of angelica sinensis extract, 0.01-0.4 part of agilawood extract, 0.01-0.5 part of black grass seed extract and 0.01-0.5 part of holy basil extract.
Further, the coating comprises the following components in parts by weight: 10.1 parts of biotin tripeptide, 170.2 parts of myristoyl pentapeptide, 0.05 part of glossy privet fruit extract, 0.05 part of eclipta extract, 0.05 part of cortex dictamni extract, 0.05 part of radix sophorae flavescentis extract, 0.05 part of cortex mori extract, 0.05 part of cacumen biotae extract, 0.05 part of polygonum multiflorum extract, 0.05 part of angelica extract, 0.03 part of agilawood extract, 0.05 part of nigella sativa seed extract and 0.05 part of holy basil extract.
The second purpose of the invention is realized by adopting the following technical scheme:
a preparation of the composition for improving the hair loss and the hair growth of the human comprises the following components in parts by weight: 0.2-12 parts of composition for improving alopecia and growing hair, 25-45 parts of surfactant, 0.1-1 part of panthenol, 0.1-5 parts of hair conditioner, 0.5-3 parts of oil agent, 0.1-1 part of preservative and 40-70 parts of water.
Further, the surfactant is sodium methyl cocoyl taurate and/or cocamidopropyl betaine; the hair conditioner is polyquaternium-67 and/or polyquaternium-10; the oil agent is PPG-3 octyl ether; the preservative is sodium benzoate and/or benzyl alcohol.
Further, the coating comprises the following components in parts by weight: 10.05-1 parts of biotin tripeptide, 0.01-1 part of myristoyl pentapeptide-170.05-1 part of glossy privet fruit extract, 0.01-1 part of eclipta extract, 0.01-1 part of cortex dictamni extract, 0.01-1 part of radix sophorae flavescentis extract, 0.01-1 part of cortex mori extract, 0.01-1 part of cacumen biotae extract, 0.01-1 part of polygonum multiflorum extract, 0.01-1 part of angelica extract, 0.01-1 part of agilawood extract, 0.01-1 part of nigella sativa seed extract, 0.01-1 part of holy basil extract, 15-25 parts of methyl cocoyl sodium taurate, 10-20 parts of cocamidopropyl betaine, 0.1-1 part of panthenol, 0. 670.05-3 parts of polyquaternary ammonium salt-100.05-2 parts of polyquaternary ammonium salt, 0.5-3 parts of PPG-3 octyl ether, 0.05-0.5 part of sodium benzoate, 0.05-0.5 part of benzyl alcohol and 50-70 parts of water.
Further, the coating comprises the following components in parts by weight: 10.1 parts of biotin tripeptide, 170.2 parts of myristoyl pentapeptide, 0.05 part of glossy privet fruit extract, 0.05 part of eclipta extract, 0.05 part of cortex dictamni extract, 0.05 part of radix sophorae flavescentis extract, 0.05 part of cortex mori extract, 0.05 part of cacumen biotae extract, 0.05 part of polygonum multiflorum extract, 0.05 part of angelica sinensis extract, 0.03 part of agilawood extract, 0.05 part of nigella sativa seed extract, 0.05 part of holy basil extract, 20 parts of sodium methyl cocoyl taurate, 15 parts of cocamidopropyl betaine, 0.2 part of panthenol, 670.2 parts of polyquaternium salt, 100.1 parts of polyquaternium, 0.8 part of PPG-3 octyl ether, 0.3 part of sodium benzoate, 0.4 part of benzyl alcohol and 62.22 parts of water.
The third purpose of the invention is realized by adopting the following technical scheme:
a method for preparing a preparation for improving hair loss and hair growth of a human comprises the following steps:
a dissolving step: mixing the surfactant, the panthenol and the water according to the formula ratio, fully stirring to enable the mixture to be dissolved uniformly, and heating to 50-60 ℃ to obtain a first mixture; mixing the hair conditioner, the oil agent and the preservative according to the formula amount, fully stirring to enable the hair conditioner, the oil agent and the preservative to be dissolved uniformly, and heating to 50-60 ℃ to obtain a second mixture;
mixing: stirring the first mixture and synchronously adding the second mixture, homogenizing for 3-10 minutes, preserving heat for 10-30 minutes, and cooling to obtain a third mixture; when the temperature of the third mixture is reduced to 40-50 ℃, adding the traditional Chinese medicine extracts in the formula amount, and uniformly stirring to obtain a fourth mixture; and (3) when the temperature of the fourth mixture is reduced to 30-40 ℃, adding the biotin tripeptide-1 and the myristoyl pentapeptide-17 according to the formula amount, and uniformly stirring to obtain the composition.
The fourth purpose of the invention is realized by adopting the following technical scheme:
the composition for improving the human hair loss and growing the hair is applied to a hair loss prevention and growing product, and the hair loss prevention and growing product comprises shampoo, hair conditioner, hair care essential oil, hair mask, eyebrow growing liquid and eyelash growing liquid.
Compared with the prior art, the invention has the beneficial effects that:
(1) the composition for improving the human hair loss and growing the hair provided by the invention has the advantages that the biotin tripeptide-1, the myristoyl pentapeptide-17 and the traditional Chinese medicine extracts take effect synergistically, the secretion function of sebaceous glands can be influenced by adjusting the local sex hormone level in the skin tissue of a human body, the hair loss number of a seborrheic alopecia patient can be obviously reduced, the clinical symptoms such as hair oil, dandruff, head itch and the like are improved, the curing time is shortened, the curing rate is greatly improved, and the composition finally achieves the clinical effects of removing fat, preventing the hair loss and promoting the hair growth. Meanwhile, the composition is green and environment-friendly, does not contain conazol, antibiotic hormones and medicinal components, has no risk of drug resistance and drug resistance, is safe and reliable, and has no adverse reaction.
(2) The preparation method of the preparation for improving the alopecia and the hair growth of the human body provided by the invention has simple and convenient process and is beneficial to industrial production.
(3) The composition for improving the human hair loss and growing the hair can be applied to various products for preventing the hair loss and growing the hair, comprises shampoo, hair conditioner, hair care essential oil, hair mask (hairdressing gel), eyebrow growing liquid, eyelash growing liquid and the like, and has wide application range.
Drawings
FIG. 1 is a diagram of a Hamilton typing standard for men according to an embodiment of the present invention;
fig. 2 is a female Ludwig typing standard diagram provided by the embodiment of the invention.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and the detailed description, and it should be noted that any combination of the embodiments or technical features described below can be used to form a new embodiment without conflict. The raw materials, equipments and the like used in the following examples are commercially available unless otherwise specified.
A composition for improving alopecia and promoting hair growth of a human comprises the following components in parts by weight: 10.05-1 parts of biotin tripeptide, 170.05-1 parts of myristoyl pentapeptide, 0.01-1 parts of glossy privet fruit extract, 0.01-1 parts of eclipta extract, 0.01-1 parts of cortex dictamni extract, 0.01-1 parts of radix sophorae flavescentis extract, 0.01-1 parts of cortex mori extract, 0.01-1 parts of cacumen biotae extract, 0.01-1 parts of polygonum multiflorum extract, 0.01-1 parts of angelica extract, 0.01-1 parts of agilawood extract, 0.01-1 parts of nigella sativa seed extract and 0.01-1 parts of holy basil extract.
The composition for improving the alopecia and the hair growth of the human provided by the embodiment of the invention can adopt external powder and paste, can directly act on an affected part, has obvious effect and is particularly effective to androgenetic alopecia (seborrheic alopecia).
The composition for improving the human hair loss and growing the hair provided by the embodiment of the invention can be applied to products for preventing the hair loss and growing the hair, and comprises shampoo, hair conditioner, hair care essential oil, hair mask (hairdressing gel), eyebrow growing liquid, eyelash growing liquid and the like.
The english name of biotin Tripeptide-1 is biotin Tripeptide-1, also known as Procapil (hair-growing peptide), whose hair growth mechanism includes the following points: biotinoyl Tripeptide-1 has a positive effect on hair follicles by promoting scalp microcirculation and reducing follicle atrophy and senescence; biotinoyl Tripeptide-1 helps to slow the aging effect by reducing the production of Dihydrotestosterone (DHT) to improve the irrigation of hair follicles. Research shows that the product can: increase hair growth, enhance adhesion molecules, stimulate hair enhancement genes, increase the proportion of hair growth; 3. biotin is essential for cell growth, fatty acid production, and metabolism of fats and amino acids. It plays a role in the citric acid cycle, which is the process of generating biochemical energy during aerobic respiration. Biotin not only helps in various metabolic reactions, but also helps in the transfer of carbon dioxide.
Myristoyl pentapeptide-17, also known as myristoyl pentapeptide-1, is also known as eyelash peptide and can significantly activate keratin gene, promote its expression and increase growth of eyelashes and hair papilla. It also accelerates hair growth and thickens hair when used in hair care products.
The traditional Chinese medicine extract provided by the embodiment of the invention comprises the following traditional Chinese medicine components: glossy privet fruit, yerbadetajo herb, dittany bark, lightyellow sophora root, white mulberry root-bark, Chinese arborvitae twig, Chinese angelica, Chinese eaglewood, nigella sativa seed and holy basil, which are named as Wumishu. Wumishu is a traditional Chinese medicine compound extract developed by the applicant according to the traditional Chinese medicine theory and clinical practice. The raw material medicaments used in the embodiment of the invention can be purchased from Chinese medicinal shops and Chinese medicinal material markets, the specifications of the raw material medicaments conform to the national Chinese medicinal material pharmacopoeia standard, and the raw material medicaments are extracted by deionized water. In addition, all the traditional Chinese medicine extracts and microbial fermentation products in the embodiment of the invention are in the catalog of cosmetic raw materials 2015.
The Wumishu composition is a natural cosmetic raw material, is rich in volatile oil, saponin, alkaloid and iridoid components, can clean dirt on hair epidermis, promote blood circulation of hair follicles, has the effects of inhibiting bacteria and relieving itching, enables the hair follicles to have a comfortable growth environment, effectively supplements nutrient components required by the hair, can improve the hair quality and prevent the hair from falling off after long-term use, has the effects of nourishing and growing hair, and enables the hair to be blacker, smooth and glossy after shampooing, protecting and growing the hair. The method specifically comprises the following steps:
the Wumishu formula has the effects of nourishing yin, tonifying kidney, promoting blood circulation, removing blood stasis, promoting scalp blood circulation and inhibiting 5 alpha-reductase. The Wumishu prescription is firstly combined by glossy privet fruit and eclipta, and the combination of the two prescriptions is famous in ancient times, and comes from the medical prescription integration of Qing Dynasty, and is recorded as the second prescription because glossy privet fruit is collected in winter solstice and eclipta is collected in summer solstice. Square-in-the-middle cloud: the medicine for treating scanty yin also has glossy privet, is sweet and mild, has the effects of reducing yin essence, lowering winter, preventing withering, and has a dark color, and is beneficial to liver and kidney; the herba Ecliptae is sweet and cold, and its juice black in kidney and replenishing essence, so it can tonify the lower qi and nourish the upper qi, strengthen yin and blacken hair.
The glossy privet fruit is neutral in nature, sweet and bitter in taste, enters liver and kidney meridians, and has the effects of nourishing yin, prolonging life, tonifying liver and kidney, clearing heat, improving eyesight, blackening beard and hair and the like. Therefore, fructus Ligustri Lucidi is commonly used to treat dizziness, tinnitus, blurred vision, soreness and pain of the waist and knees, internal heat, early graying of hair, etc. The Shen nong Ben Cao Jing is listed as the superior product. The glossy privet fruit is considered to have the effects of strengthening the middle-jiao, calming the five internal organs, nourishing the spirit and eliminating hundreds of diseases. The glossy privet fruit can nourish liver and kidney, calm five internal organs, strengthen waist and knees, improve eyesight and ears, blacken beard and hair, tonify wind deficiency and remove diseases in the herbal preparation. According to the theory of 'tonifying in shape' in traditional Chinese medicine, the glossy privet fruit which is used as a medicine is extremely like the kidney of a human body, and can tonify the kidney and strengthen the body naturally. The herbal Jing Shu (herbal Jing Shu) states that: "glossy privet fruit has both yin smell and is essential for kidney to remove heat and replenish essence, and when kidney is tonified, five zang organs are self-pacified, spirit is self-sufficient, and all diseases are cured and body is fattened . The modern pharmacological research shows that the glossy privet fruit is rich in terpenoid components such as oleanolic acid and the like, phenethyl alcohol glycoside components such as salidroside and the like, and a large amount of flavonoid components such as quercetin, taxifolin, apigenin and the like.
Ecliptae herba, also known as Ecliptae herba, is sweet, sour and cold in nature. It enters kidney and liver meridians. Ancient books are recorded respectively: tang Ben Cao (materia Medica of Tang Dynasty): sweet and sour, mild and nontoxic. The Yunnan herbal medicine: cold in nature and salty in taste. Enter liver and kidney meridians. Ben Cao Jing Shu (the book of materia Medica Prime and Dredging): enter kidney and liver. Stomach, large and small intestine. Des-join materia Medica: enter the blood system of foot-shaoyin channel. At present, the traditional Chinese medicine is mainly used for nourishing liver and kidney, cooling blood and stopping bleeding. The Chinese medicinal composition is used for treating odontoseisis, premature graying of beard and hair, dizziness and tinnitus, waist and knee soreness, yin deficiency and blood heat, hematemesis, epistaxis, hematuria, bloody dysentery, metrorrhagia and metrostaxis and traumatic hemorrhage, is also a traditional Chinese medicine frequently used for traditional Chinese medicine hair care and hair care, is rich in wedelolactone, triterpenoid saponin and steroid components, and is found in modern researches that the eclipta has a remarkable activation effect on tyrosinase (tyrpase) which is a key enzyme for melanin synthesis, and also proves that the eclipta has the effect of promoting the white hair to turn into black hair.
In addition, the Wumishu formula also comprises the components of cacumen biotae, angelica, cortex mori radicis, radix sophorae flavescentis and the like, the combination of the cacumen biotae and the angelica is a traditional famous formula two-immortal formula from ancient and modern medical science and technology, and is a classic external formula for treating dandruff and alopecia, wherein the angelica has the effects of enriching blood, activating blood circulation, relaxing muscles and tendons, can expand scalp capillaries and promote blood circulation, contains rich trace elements, can nourish hair follicle cells and promote metabolism.
Folium Platycladi can relax smooth muscle, block action of choline acetate on smooth muscle, improve hair follicle growth, and inhibit Staphylococcus aureus and Candida albicans. The leaves of Platycladus orientalis were recorded in Shen nong Ben Cao Jing (Shen nong's herbal), and they are the dry tips and leaves of Platycladus orientalis of Cupressaceae. The compendium of materia Medica records that the Chinese arborvitae twig is mainly used for treating hair loss. In Ben Cao Tong Xuan (herbal medicine for promoting the secretion of saliva), Ce Bai Ye can blacken the temples and blacken the hair. The main chemical components of the cacumen biotae are tannin, flavone, volatile oil and the like, which are recorded in Chinese pharmacopoeia 2010 edition and have the effects of cooling blood, stopping bleeding, growing hair and blackening hair. Can be used for treating alopecia due to blood heat and premature gray hair. It is suitable for growing and blackening hair. The main pharmacological activities of the cacumen biotae comprise the functions of hemostasis, anti-inflammation, bacteriostasis, erythrocyte oxidation resistance, tumor resistance and the like. Is consistent with the traditional Chinese medicine theory that the cacumen biotae stops bleeding, reduces phlegm and the like. The cacumen biotae can clear heat and cool blood, so the cacumen biotae is a good product for treating blood dryness and alopecia. There is a record of the use of cacumen biotae for hair growth as early as in the book of cubitus rear: taking cacumen Platycladi, drying in the shade to obtain powder, and coating with oil. Researches on Zhaoyangguang and the like believe that the main chemical components of the cacumen biotae playing the roles of growing and blacking hair are total flavonoid components in the cacumen biotae. The hair growth and blacking mechanism can activate hair mother cells, promote blood circulation of scalp parts, repair declined hair follicles and promote blood circulation around the hair follicles so as to increase nutrition supply of head skin to achieve the aims of hair growth and blacking.
Cortex Dictamni Radicis and radix Sophorae Flavescentis have effects of clearing heat, promoting diuresis, relieving itching, and enhancing antibacterial and itching relieving effects, and cortex Mori has effect of enhancing scalp health. Cortex mori radicis sweet and cold in flavor and enters lung and spleen meridians, can moisten skin and hair by external application, nourish yin and grow hair, is recorded in Waitai secret to be decocted with cortex mori radicis for bathing hair so as to treat deficient cold in vessels and fall down on hair, is recorded in Bei Ji Qian jin Yao Fang for bathing hair so as to treat hair loss, and is recorded in Tai Ping Sheng Hui for treating hair loss, wherein the cortex mori radicis and the cypress leaves are respectively one jin and are decocted and moistened when being used for bathing. Meanwhile, the plant extract used in the embodiment of the invention can promote blood circulation, improve the activity of scalp cells, regulate the metabolism of the scalp cells, improve the microenvironment of the scalp and prolong the life cycle of the scalp cells, thereby internally reducing the generation of dandruff and scalp itch.
The agilawood and the agilawood are rich in natural essential oil components such as monoterpene, sesquiterpene, phenolic acid and the like, can permeate into the deep layer of scalp, clear grease, dredge hair follicles, promote qi and blood circulation, have the effects of growing and nourishing hair with the effect of turning white into black and less into more, and the formula for blackening hair can fundamentally solve the problems of alopecia and early whitening of black hair, and has profound significance for hair health and body health. The applicant carries out animal pharmacological experiments, and tests are carried out by adopting a mouse unhairing test, and the results show that the agilawood remarkably increases the weight of hairs in an administration area, activates hair follicles, improves the miniaturization of the hair follicles, promotes the growth of the hair follicles, can promote the proliferation of endothelial cells of humanized venous blood vessels, thereby promoting angiogenesis, enabling nutrient substances to reach the skin of the head and ensuring the sufficient blood supply of the hair follicles. Meanwhile, the results show that the action mechanism of the agilawood capable of promoting hair growth is probably related to promoting vascular endothelial cell proliferation, nourishing hair follicles, improving hair follicle miniaturization and promoting hair follicle growth, and lays a foundation for further researching the material basis and the hair growth mechanism of the agilawood. In addition, the cell molecular research shows that the agilawood has the effect of promoting the proliferation of Human Umbilical Vein Endothelial Cells (HUVEC). A great deal of scientific research proves that the proliferation and migration of vascular endothelial cells are not only necessary for forming blood vessels, but also can play a plurality of functions such as regulating the contraction and relaxation of blood vessels, regulating normal physiological functions and regulating the physiological functions of blood vessels by synthesizing a plurality of vasoactive substances such as nitric oxide and the likeRegulating vascular permeability, etc. The blood vessels around the hair follicle play an important role in hair growth, and are responsible for supplying nutrients required for hair growth to the hair follicle and hair, while carrying away metabolic waste products. Modern medicine considers that hair nourishing depends on blood supply, hair absorption and nutrient channel blockage are root causes of alopecia and white hair, and perifollicular blood vessels are formed in large quantity in the early stage of hair growth and are changed correspondingly along with the periodic circulation of hair follicles. The main function of the hair follicle is to form blood vessels around the hair follicle of the hair tissue and accelerate the hair regeneration after depilation, and in conclusion, the action mechanism of the agilawood for promoting the hair growth and the hair whitening and blackening is probably related to the promotion of endothelial cells of blood vessels, so that the angiogenesis and the synthesis of vasoactive substances are promoted, the blood supply of the hair follicle is increased, the microcirculation and the vascular permeability are improved, and the nutrient substances reach the skin of the head. In addition, researches show that the agilawood can influence the growth of the PC12 cell, and the PC12 cell is a rat adrenal chromaffin tumor cell line, is a good cell model for researching the physiology, pathology and pharmacology of nerve cells, has the advantages of easiness in obtaining, passability and the like, and is widely used for researches on nerve cell apoptosis and nerve protection at present. In recent years, more and more researchers build an oxidative stress injury model based on PC12 cells to research the protective effect of drugs on intracellular oxidative stress injury so as to discuss the action mechanism of the drugs. Experimental research shows that the agilawood can promote the growth of normal PC12 cells and improve COCl2The survival rate of the PC12 cells after the injury can effectively relieve oxidative stress injury caused by COCl 2. The action mechanism of the agilawood capable of growing and blackening the hair can be that the agilawood capable of promoting the proliferation of vascular endothelial cells, promoting the growth of PC12 cells and regulating the oxidation-reduction balance in the cells can promote the angiogenesis around hair follicles, protect nerves, improve microcirculation and promote the growth of the hair follicles, so that the effect of treating the hair loss is exerted.
The Wumishu composition also comprises Xinjiang traditional special traditional Chinese medicine, namely nigella sativa seeds, Uygur nationality common medicinal materials, also known as siya denier, and at present, the medicinal materials comprise three types of nigella glandulifera freyn (also called glandular hair nigella sativa), nigella sativa (also called home nigella sativa) and nigella sativa. Wherein the dry mature seeds of nigella glandulifera Freyn, recorded in the 2010 version of the Chinese pharmacopoeia. The semen Nigellae is dry mature seed of Nigella glandulifera Freyn of Ranunculaceae. Nigella sativa L.is distributed in Xinjiang in China, and is traditionally used for hair growth and hair blackening treatment. The black seed weed in the pharmacopoeia of China has the effects of tonifying kidney and strengthening brain, stimulating the menstrual flow, promoting lactation and inducing diuresis. Can be used for treating tinnitus, amnesia, amenorrhea, hypogalactia, heat stranguria, and urolithic stranguria. The black grass seeds and black grass seeds are studied earlier abroad, and in recent years, China has increasingly researched the black grass seeds, but most of the researches are focused on basic researches such as chemical components and quality standards, and the pharmacological activity and action mechanism of the black grass seeds are reported less and still need to be further researched. The research indicates that the nigella sativa seeds have pharmacological effects of eliminating phlegm, relieving cough, resisting oxidation, resisting inflammation, resisting tumor and the like. Researchers also use the petroleum ether part of nigella sativa seeds for developing nasal drops for treating rhinitis. The long-term use of black grass seeds in Uygur medicine records in the 1999 edition of Liu Yongmin, the drug Standard, the Uygur medicine book, contains 2 compound preparations for treating alopecia and alopecia, and the two preparations respectively contain black grass seeds, namely compound siya hair tonic oil and compound siya hair tonic tincture. Experimental studies have confirmed that the compound siyadan hair growth tincture has a certain effect of promoting the growth of the hair of rats. In Xinjiang, Uighur medicine compound Simidan hair tonic mainly prepared from nigella sativa seeds and single preparation Simidan injection are also clinically applied to treatment of vitiligo.
He shou Wu, He shou Wu is the dried root tuber of He shou Wu in the family of Malvaceae, beginning with Kai Bao Ben Cao (materia Medica of Kaibao). Also called shou Wu, Di Jing and He Xiang He. The record of fleece-flower root in compendium of materia Medica is as follows: the product has bitter and astringent taste, and has effects in nourishing blood, benefiting liver, stopping nocturnal emission, invigorating kidney, strengthening tendons and bones, and blackening hair. The prepared fleece flower root recorded in the 2010 version of the Chinese pharmacopoeia has the effects of tonifying liver and kidney, benefiting essence and blood, blackening beard and hair, strengthening muscles and bones and the like, and can be used for early whitening of beard and hair. Many Chinese herbal compound preparations or products for growing and blackening hair contain fleece-flower root. Since ancient times, polygonum multiflorum and processed polygonum multiflorum are used for treating alopecia and blacking hair. Many researches on polygonum multiflorum have been carried out in recent years, and the mechanisms of hair growth and hair blacking and the main active ingredients of the polygonum multiflorum are reported. The main chemical components contained in Polygoni Multiflori radix include anthraquinone, flavonoid, stilbene, and phospholipid. Among them, stilbene glucoside, which is a typical representative of stilbene in polygonum multiflorum, has received extensive attention from researchers, and many related research results. Stilbene glucoside is used as a quantitative index of the quality standard of polygonum multiflorum in the 2010 edition of Chinese pharmacopoeia. Studies believe that stilbene glucoside is an active ingredient for blackening hair and has the effect of promoting melanogenesis of melanoma cells. The stilbene glucoside can change the conformation of the levodopa in a solution state to increase the number of effective molecules collided by the levodopa and the tyrosinase. Modern medical research finds that the pharmacological activities of the stilbene glucoside comprise the effects of protecting the liver, relaxing blood vessels, protecting nerves, resisting oxidation, eliminating free radicals, reducing blood fat, resisting atherosclerosis, improving memory function and the like. Is consistent with the theory of tonifying liver and kidney and benefiting essence and blood in traditional Chinese medicine.
Holy basil, which is a characteristic traditional Chinese medicine resource in the Hunan area. The holy county is ancient, and the prefecture includes regions from Yongzhou to Guangxi quanzhou in Hunan province, the region is rich in fragrant herbs which are 'holy incense', the holy incense is a traditional spice with strong and lasting fragrance, and is a traditional Chinese medicinal material capable of relieving exterior syndrome, relieving pain, promoting qi circulation, expelling ascaris and the like, and meanwhile, the Chinese medicinal material has a special anti-corrosion effect. The Jiuxiang anti-fouling powder recorded in Zhongzi (Tibetan classic) in spring and autumn, wherein Jiuxiang has the flavor of holy basil; ming Dynasty recorded in Ben Cao gang mu recorded that the herb is fragrant and pungent and dispersing in qi, so it is indicated for aversion to qi in heart and abdomen, toothache and nasal obstruction. The holy basil incense is rich in volatile essential oil components, can quickly permeate into the scalp when being externally applied to the scalp, and can promote blood circulation, and the coumarins in the holy basil incense also have the effects of resisting bacteria, resisting inflammation, resisting coagulation and the like. Ancient medical records of China, such as Waitai Secretarian, Yi Fang Ju and Qian jin Yi Fang, have been recorded in the book of the external use of holy basil for treating alopecia.
Examples 1 to 3 and comparative examples 1 to 5
Examples 1-3 and comparative examples 1-5 disclose a formulation for improving hair loss and hair growth in humans, the specific formulation of which is shown in table 1 below.
Table 1 formulation of preparations for improving hair loss and growing hair in human of examples 1 to 3 and comparative examples 1 to 5
The preparations for improving hair loss and growing hair of human of examples 1 to 3 and comparative examples 1 to 5 were prepared according to the following methods:
fully stirring the component A to be uniformly dissolved, and heating to 55 ℃ to obtain a first mixture; mixing the component B, stirring uniformly, and heating to 55 ℃ to obtain a second mixture; then adding the second mixture into the first mixture while stirring the first mixture, homogenizing for 5 minutes, preserving the heat for 20 minutes, and then cooling to obtain a third mixture; after the temperature of the third mixture is reduced to 45 ℃, adding the component D and uniformly stirring to obtain a fourth mixture; and (4) after the temperature of the fourth mixture is reduced to 35 ℃, adding the component C and uniformly stirring to obtain the catalyst.
Effect testing
1. Physical and chemical index test
TABLE 2 record of physicochemical Properties of the preparations for improving hair loss and growing Hair for human of examples 1 to 3 and comparative examples 1 to 5
2. Chick embryo chorioallantoic membrane test
2.1 detection basis: SN/T2329-2009 test of cosmetic eye irritation/corrosivity of chick embryo chorioallantoic Membrane
2.2. Experimental materials:
2.2.1 chick embryo: SPF grade White schoolchicken (White Leghorn chicken) purchased from beijing berg ringer minghanton biotechnology limited, production license number: SCXK (Jing) 2014-.
2.2.2 culture conditions: the temperature of the incubator is 37.5 +/-0.5 ℃, and the relative humidity is 55-70%.
2.2.3 reagents and controls:
positive Control (PC): 0.1mol/LNaOH solution.
Negative Control (NC): 0.9% NaCl solution. Test sample (TA 1-example 1, TA 2-example 2, TA 3-example 3): diluted to 2% with purified water.
2.3. The test steps are as follows:
2.3.1 CAM preparation: 0 d-old chick embryos are purchased and incubated to 9 d-old chick embryos, and defective chick embryos are inspected and discarded. Marking the position of an air chamber on the surface of a normal chick embryo egg shell, peeling off the egg shell part, and exposing a white egg membrane; the intima is carefully removed with forceps to ensure that the vascular membrane is not damaged.
2.3.2 official test: at least 6 embryos per group, 0.3 mL of the test substance as received was directly dropped onto the CAM surface, the CAM reaction was observed and the time to each toxic effect within 5min of action was recorded to the nearest second, including 3 reactions of bleeding, clotting and vessel thawing, and the extent of the reaction was recorded. The same procedure was used for the positive and negative controls.
2.3.3 data analysis: recording the time of appearance and the degree of response of each detection endpoint, calculating the stimulation score (IS) using the following formula, and retaining the last two decimal points as a result:
sec H, sec L and sec C represent the average time (seconds) at which bleeding, vessel thawing and clotting were observed on the CAM membrane, respectively.
TABLE 3 evaluation of stimulation scoring results
Stimulation score IS | Prediction classification |
IS<1 | Nonirritating Non-irritant (NI) |
1≤IS<5 | Mild irritancy Slightly Irritant (SI) |
5≤IS<9 | Moderate irritancy Modern Irritant (MI) |
IS≥10 | Strong irritant/corrosive Strong irritant/Corrosive (Co) |
2.4 test results:
TABLE 4 test results record table
2.5. Conclusion
According to the judgment standard of SN/T2329-2009, under the experimental conditions, the IS score of the test sample of examples 1-3 IS 0, and the test sample IS nonirritating.
3. Alopecia treatment efficacy test
112 seborrheic alopecia patients with unlimited age were selected by classifying and classifying the existing cosmetics, and 30 men and 12 women in each group were tried with the preparations for improving alopecia and growing hair of people in examples 1-3 and comparative examples 1-5, respectively.
TABLE 5 grouping status record Table for alopecia treatment group
The diagnostic criteria were as follows:
1. hair thinning or even balding;
2. although the hair is not obviously sparse, the hair is obviously shed recently, and the hair is obviously reduced compared with the prior hair;
3. increased dandruff;
4. the hair is bright, and the scalp grease is obvious;
5. itching of the scalp;
the patients who conform to the first 2 strips and have more than the last 3 strips can be diagnosed as seborrheic alopecia
Grading standard of seborrheic alopecia:
1. the male is classified into 7 grades and 13 grades according to Hamilton typing standard, and the classification is shown in figure 1;
2. women were classified into 3 grades according to the Ludwig typing standard, as shown in FIG. 2.
The using method comprises the following steps:
external washing: for patients with abundant hair, washing hair, adding water 20ml, spraying on scalp and hair root, beating with hand, massaging for 3-5 min, and washing with water once a day;
externally applying: the shampoo is used for patients with sparse hair and severe alopecia, the bald part is cleaned, the liquid medicine is directly coated on the bald part, and the massage is carried out for 5 to 10 minutes, so that the scalp fully absorbs the active ingredients, and the shampoo is used once a day, preferably before sleeping at night;
one month is a treatment course, and 2 to 3 treatment courses are common.
Remarking: for patients with alopecia with abundant hair, the external washing method is convenient to use because the hair loss part is not clear, and the liquid medicine can fully permeate the whole hair and has long retention time, thereby exerting the drug effect. Patients with thin hair and baldness have definite baldness positions, and the external application method aims at high-concentration and continuous medication, stimulating hair follicles and accelerating hair growth. The medicine is applied in combination with massage, and can promote scalp blood circulation and facilitate medicine absorption.
TABLE 6 therapeutic efficacy criteria
TABLE 7 therapeutic effect recording sheet
According to test results, the preparation for improving alopecia and growing hair of people provided by the embodiment of the invention has good treatment effect on seborrheic alopecia and other alopecia of men and women, the effective rate can reach more than 85% 7, and particularly the effective rate of the embodiment 1 reaches 92.9%. The formula of the comparative example 1 only contains the components A and B, does not contain the active components C and D, and has the effective rate of less than 30 percent. Comparative example 2 the prescription has no C component, namely biotin tripeptide-1 and myristoyl pentapeptide-17, and the effective rate is only 35.7%; the formula of the comparative example 3 has no D component, and the effective rate is only 28.6 percent; comparative example 4 no agilawood extract is contained in the formula, and the effective rate is 35.7%; the formula of the comparative example 5 does not contain nigella sativa seed extract and holy basil extract, and the effective rate is less than 30%. It can be seen that the components in the examples 1-3 are synergistic, and are matched with each other to jointly inhibit alopecia and promote hair growth, and the formula of the examples 1-2 is green and environment-friendly, does not contain the hormone and medicinal components of the ketoconazole and the antibiotics, has no risk of drug resistance and drug resistance, and is safe and reliable without adverse reaction. Researches find that the biotin tripeptide-1, myristoyl pentapeptide-17 and the Wumishu composition (component D, a traditional Chinese medicine extract composition) can influence the secretion function of sebaceous glands by adjusting the local sex hormone level in human skin tissues, can obviously reduce the hair loss number of seborrhoeic alopecia patients, improve the clinical symptoms of hair oil, dandruff, head itch and the like, shorten the curing time, greatly improve the curing rate and finally achieve the clinical effects of removing fat, preventing alopecia and promoting hair growth.
The above embodiments are only preferred embodiments of the present invention, and the protection scope of the present invention is not limited thereby, and any insubstantial changes and substitutions made by those skilled in the art based on the present invention are within the protection scope of the present invention.
Claims (10)
1. The composition for improving the hair loss and the hair growth of the human is characterized by comprising the following components in parts by weight: 10.05-1 parts of biotin tripeptide, 170.05-1 parts of myristoyl pentapeptide, 0.01-1 parts of glossy privet fruit extract, 0.01-1 parts of eclipta extract, 0.01-1 parts of cortex dictamni extract, 0.01-1 parts of radix sophorae flavescentis extract, 0.01-1 parts of cortex mori extract, 0.01-1 parts of cacumen biotae extract, 0.01-1 parts of polygonum multiflorum extract, 0.01-1 parts of angelica extract, 0.01-1 parts of agilawood extract, 0.01-1 parts of nigella sativa seed extract and 0.01-1 parts of holy basil extract.
2. The composition for improving hair loss and growing hair in a human according to claim 1, which comprises the following components in parts by weight: 10.05-0.8 part of biotin tripeptide, 170.05-0.8 part of myristoyl pentapeptide, 0.01-0.5 part of glossy privet fruit extract, 0.01-0.5 part of eclipta extract, 0.01-0.5 part of cortex dictamni extract, 0.01-0.5 part of radix sophorae flavescentis extract, 0.01-0.5 part of cortex mori extract, 0.01-0.5 part of cacumen biotae extract, 0.01-0.5 part of polygonum multiflorum extract, 0.01-0.5 part of angelica sinensis extract, 0.01-0.4 part of agilawood extract, 0.01-0.5 part of black grass seed extract and 0.01-0.5 part of holy basil extract.
3. The composition for improving hair loss and growing hair in a human according to claim 1, which comprises the following components in parts by weight: 10.1 parts of biotin tripeptide, 170.2 parts of myristoyl pentapeptide, 0.05 part of glossy privet fruit extract, 0.05 part of eclipta extract, 0.05 part of cortex dictamni extract, 0.05 part of radix sophorae flavescentis extract, 0.05 part of cortex mori extract, 0.05 part of cacumen biotae extract, 0.05 part of polygonum multiflorum extract, 0.05 part of angelica extract, 0.03 part of agilawood extract, 0.05 part of nigella sativa seed extract and 0.05 part of holy basil extract.
4. A formulation using the composition for improving hair loss and growing hair in humans according to any one of claims 1 to 3, comprising the following components in parts by weight: 0.2-12 parts of composition for improving alopecia and growing hair, 25-45 parts of surfactant, 0.1-1 part of panthenol, 0.1-5 parts of hair conditioner, 0.5-3 parts of oil agent, 0.1-1 part of preservative and 40-70 parts of water.
5. The formulation of claim 4, wherein the surfactant is sodium methyl cocoyl taurate and/or cocamidopropyl betaine; the hair conditioner is polyquaternium-67 and/or polyquaternium-10; the oil agent is PPG-3 octyl ether; the preservative is sodium benzoate and/or benzyl alcohol.
6. The formulation of claim 5, comprising the following components in parts by weight: 10.05-1 parts of biotin tripeptide, 0.01-1 part of myristoyl pentapeptide-170.05-1 part of glossy privet fruit extract, 0.01-1 part of eclipta extract, 0.01-1 part of cortex dictamni extract, 0.01-1 part of radix sophorae flavescentis extract, 0.01-1 part of cortex mori extract, 0.01-1 part of cacumen biotae extract, 0.01-1 part of polygonum multiflorum extract, 0.01-1 part of angelica extract, 0.01-1 part of agilawood extract, 0.01-1 part of nigella sativa seed extract, 0.01-1 part of holy basil extract, 15-25 parts of methyl cocoyl sodium taurate, 10-20 parts of cocamidopropyl betaine, 0.1-1 part of panthenol, 0. 670.05-3 parts of polyquaternary ammonium salt-100.05-2 parts of polyquaternary ammonium salt, 0.5-3 parts of PPG-3 octyl ether, 0.05-0.5 part of sodium benzoate, 0.05-0.5 part of benzyl alcohol and 50-70 parts of water.
7. The formulation of claim 6, comprising the following components in parts by weight: 10.1 parts of biotin tripeptide, 170.2 parts of myristoyl pentapeptide, 0.05 part of glossy privet fruit extract, 0.05 part of eclipta extract, 0.05 part of cortex dictamni extract, 0.05 part of radix sophorae flavescentis extract, 0.05 part of cortex mori extract, 0.05 part of cacumen biotae extract, 0.05 part of polygonum multiflorum extract, 0.05 part of angelica sinensis extract, 0.03 part of agilawood extract, 0.05 part of nigella sativa seed extract, 0.05 part of holy basil extract, 20 parts of sodium methyl cocoyl taurate, 15 parts of cocamidopropyl betaine, 0.2 part of panthenol, 670.2 parts of polyquaternium salt, 100.1 parts of polyquaternium, 0.8 part of PPG-3 octyl ether, 0.3 part of sodium benzoate, 0.4 part of benzyl alcohol and 62.22 parts of water.
8. A method of preparing a preparation according to claim 4 for ameliorating hair loss and promoting hair growth in a human comprising:
a dissolving step: mixing the surfactant, the panthenol and the water according to the formula ratio, fully stirring to enable the mixture to be dissolved uniformly, and heating to 50-60 ℃ to obtain a first mixture; mixing the hair conditioner, the oil agent and the preservative according to the formula amount, fully stirring to enable the hair conditioner, the oil agent and the preservative to be dissolved uniformly, and heating to 50-60 ℃ to obtain a second mixture;
mixing: stirring the first mixture and synchronously adding the second mixture, homogenizing for 3-10 minutes, preserving heat for 10-30 minutes, and cooling to obtain a third mixture; when the temperature of the third mixture is reduced to 40-50 ℃, adding the traditional Chinese medicine extracts in the formula amount, and uniformly stirring to obtain a fourth mixture; and (3) when the temperature of the fourth mixture is reduced to 30-40 ℃, adding the biotin tripeptide-1 and the myristoyl pentapeptide-17 according to the formula amount, and uniformly stirring to obtain the composition.
9. The method of preparing a preparation for improving hair loss and growth in humans according to claim 8, comprising:
a dissolving step: mixing the surfactant, the panthenol and the water according to the formula ratio, fully stirring to dissolve the mixture uniformly, and heating to 55 ℃ to obtain a first mixture; mixing the hair conditioner, the oil agent and the preservative according to the formula amount, fully stirring to enable the hair conditioner, the oil agent and the preservative to be dissolved uniformly, and heating to 55 ℃ to obtain a second mixture;
mixing: stirring the first mixture and synchronously adding the second mixture, homogenizing for 5 minutes, preserving heat for 20 minutes, and cooling to obtain a third mixture; when the temperature of the third mixture is reduced to 45 ℃, adding the traditional Chinese medicine extracts in the formula amount, and uniformly stirring to obtain a fourth mixture; and (3) when the temperature of the fourth mixture is reduced to 35 ℃, adding the biotin tripeptide-1 and the myristoyl pentapeptide-17 according to the formula amount, and uniformly stirring to obtain the composition.
10. Use of the composition for improving hair loss and hair growth of human according to any one of claims 1 to 3 in hair loss prevention and hair growth products including shampoo, conditioner, hair care essential oil, hair mask, eyebrow growing liquid and eyelash growing liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110158512.0A CN112870333A (en) | 2021-02-05 | 2021-02-05 | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110158512.0A CN112870333A (en) | 2021-02-05 | 2021-02-05 | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112870333A true CN112870333A (en) | 2021-06-01 |
Family
ID=76057360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110158512.0A Pending CN112870333A (en) | 2021-02-05 | 2021-02-05 | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112870333A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113693976A (en) * | 2021-08-23 | 2021-11-26 | 上海洁士宝日化集团有限公司 | Sericin stock solution shampoo and preparation method thereof |
CN114288221A (en) * | 2022-01-10 | 2022-04-08 | 广西和桂集团有限公司 | A method for preparing essence containing polypeptide and plant extractive solution with hair growth promoting effect and its application |
CN114848554A (en) * | 2022-05-24 | 2022-08-05 | 品高生物科技(广州)有限公司 | Plant compound for preventing hair loss and growing hair and preparation method thereof |
CN116870071A (en) * | 2023-08-23 | 2023-10-13 | 广东药科大学 | Traditional Chinese medicine composition for eyebrow generation, eyebrow generation powder, and preparation method and application thereof |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005060357A (en) * | 2003-08-12 | 2005-03-10 | ▲張▼ ▲書▼廷 | Health food for promoting sleep and tranquirizing by using plant as raw material and method for producing the same |
CN101115493A (en) * | 2005-08-12 | 2008-01-30 | 河乃建仁 | Agent for hair growth |
CN102205082A (en) * | 2011-05-29 | 2011-10-05 | 朱惠芬 | External application steaming and washing agent for treating alopecia areata |
AU2012201810A1 (en) * | 2004-12-24 | 2012-04-19 | Dolphst Pty Ltd | Formulations and treatments for trichology |
CN105106028A (en) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | Polypeptide composition for hair growth |
CN105194113A (en) * | 2015-10-18 | 2015-12-30 | 十堰德远科技开发有限公司 | Jinma oral liquid for treating alopecia and preparation method of oral liquid |
CN105194552A (en) * | 2015-10-18 | 2015-12-30 | 十堰德远科技开发有限公司 | Ointment for treating alopecia and preparation method of ointment |
CN106214509A (en) * | 2016-08-24 | 2016-12-14 | 上海波林丝生物科技有限公司 | A kind of compositions promoting eyelashes to grow |
US20180050081A1 (en) * | 2014-01-23 | 2018-02-22 | The University Of Kansas | Compounds and methods for increasing hair growth |
CN108607049A (en) * | 2018-06-08 | 2018-10-02 | 欧晋 | A kind of hair growth composition and preparation method thereof |
CN110013455A (en) * | 2019-03-15 | 2019-07-16 | 珠海伊斯佳科技股份有限公司 | It is a kind of with antipruritic, oil-control, strong hair, Anti-hair loss effect composition |
CN110721238A (en) * | 2019-11-20 | 2020-01-24 | 上海华伊美化妆品有限公司 | Compound traditional Chinese medicine extract for fixing hair, preventing alopecia and removing dandruff as well as preparation method and application thereof |
CN111084726A (en) * | 2020-01-08 | 2020-05-01 | 北京幸福益生再生医学科技有限公司 | Hair loss prevention and hair growth composition and preparation method thereof |
CN111329779A (en) * | 2020-03-23 | 2020-06-26 | 烟台中科恩吉科创新产业园管理有限公司 | Active peptide composition for promoting hair growth and application thereof |
-
2021
- 2021-02-05 CN CN202110158512.0A patent/CN112870333A/en active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005060357A (en) * | 2003-08-12 | 2005-03-10 | ▲張▼ ▲書▼廷 | Health food for promoting sleep and tranquirizing by using plant as raw material and method for producing the same |
AU2012201810A1 (en) * | 2004-12-24 | 2012-04-19 | Dolphst Pty Ltd | Formulations and treatments for trichology |
CN101115493A (en) * | 2005-08-12 | 2008-01-30 | 河乃建仁 | Agent for hair growth |
CN102205082A (en) * | 2011-05-29 | 2011-10-05 | 朱惠芬 | External application steaming and washing agent for treating alopecia areata |
US20180050081A1 (en) * | 2014-01-23 | 2018-02-22 | The University Of Kansas | Compounds and methods for increasing hair growth |
CN105106028A (en) * | 2015-08-28 | 2015-12-02 | 深圳市维琪医药研发有限公司 | Polypeptide composition for hair growth |
CN105194552A (en) * | 2015-10-18 | 2015-12-30 | 十堰德远科技开发有限公司 | Ointment for treating alopecia and preparation method of ointment |
CN105194113A (en) * | 2015-10-18 | 2015-12-30 | 十堰德远科技开发有限公司 | Jinma oral liquid for treating alopecia and preparation method of oral liquid |
CN106214509A (en) * | 2016-08-24 | 2016-12-14 | 上海波林丝生物科技有限公司 | A kind of compositions promoting eyelashes to grow |
CN108607049A (en) * | 2018-06-08 | 2018-10-02 | 欧晋 | A kind of hair growth composition and preparation method thereof |
CN110013455A (en) * | 2019-03-15 | 2019-07-16 | 珠海伊斯佳科技股份有限公司 | It is a kind of with antipruritic, oil-control, strong hair, Anti-hair loss effect composition |
CN110721238A (en) * | 2019-11-20 | 2020-01-24 | 上海华伊美化妆品有限公司 | Compound traditional Chinese medicine extract for fixing hair, preventing alopecia and removing dandruff as well as preparation method and application thereof |
CN111084726A (en) * | 2020-01-08 | 2020-05-01 | 北京幸福益生再生医学科技有限公司 | Hair loss prevention and hair growth composition and preparation method thereof |
CN111329779A (en) * | 2020-03-23 | 2020-06-26 | 烟台中科恩吉科创新产业园管理有限公司 | Active peptide composition for promoting hair growth and application thereof |
Non-Patent Citations (3)
Title |
---|
JAE YOUNG SHIN 等: "Polygonum multiflorum extract support hair growth by elongating anagen phase and abrogating the effect of androgen in cultured human dermal papilla cells", 《BMC COMPLEMENT MED THER》 * |
张景岳著: "《景岳全书系列 本草正》", 30 September 2017, 中国医药科技出版社 * |
林文真 等: "防脱生发品概况", 《精细与专用化学品》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113693976A (en) * | 2021-08-23 | 2021-11-26 | 上海洁士宝日化集团有限公司 | Sericin stock solution shampoo and preparation method thereof |
CN114288221A (en) * | 2022-01-10 | 2022-04-08 | 广西和桂集团有限公司 | A method for preparing essence containing polypeptide and plant extractive solution with hair growth promoting effect and its application |
CN114848554A (en) * | 2022-05-24 | 2022-08-05 | 品高生物科技(广州)有限公司 | Plant compound for preventing hair loss and growing hair and preparation method thereof |
CN114848554B (en) * | 2022-05-24 | 2024-01-23 | 品高生物科技(广州)有限公司 | Plant compound capable of preventing hair loss and growing hair and preparation method thereof |
CN116870071A (en) * | 2023-08-23 | 2023-10-13 | 广东药科大学 | Traditional Chinese medicine composition for eyebrow generation, eyebrow generation powder, and preparation method and application thereof |
CN116870071B (en) * | 2023-08-23 | 2024-04-05 | 广东药科大学 | Traditional Chinese medicine composition for eyebrow generation, eyebrow generation powder, and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103169631B (en) | A kind of submissive glossy shampoo and preparation method containing Chinese medicine composition | |
KR100963792B1 (en) | Shampoo containing composite for growing hair and preventing fall-out of hair | |
CN112870333A (en) | Composition and preparation for improving alopecia and promoting hair growth of human, and preparation method and application thereof | |
KR101743197B1 (en) | The manufacturing method of shampoo composition for caring scalp and promoting hair growth, and shampoo composition thereof | |
KR100761660B1 (en) | A composition for promoting hair growth | |
CN102038626B (en) | Traditional Chinese medicinal hair-restoring and anti-alopecia shampoo and preparation method thereof | |
KR101744103B1 (en) | Composition for preventing hair loss and promoting hair growth and mathod for preparing the same | |
US9180087B2 (en) | Chinese medicine hair-regrowth preparation and formula and preparation method therefor | |
CN108096091B (en) | Composition containing Cordyceps extract for preventing alopecia, promoting hair growth and blackening hair, and its preparation method | |
CN106214592A (en) | Hair follicle nutrient liquor composition and preparation method thereof | |
KR100747651B1 (en) | Material compositions for hair health care and hair growth acceleration | |
CN111529477A (en) | Composition for caring hair, and preparation and application thereof | |
CN110123683A (en) | Compound natural small molecule plant extracts phalacrosis prevention and hair generation prescription and products thereof | |
CN113171329A (en) | Plant multi-effect anti-hair loss hair-growing hair-nourishing compound composition and preparation method thereof | |
CN108272700A (en) | A kind of composition and preparation method thereof with hair-loss preventing and hair-restoring, anti-dandruff and itching-relieving efficacies | |
CN107412709B (en) | Chinese herbal medicine composition with alopecia stopping and hair growth effects and preparation method thereof | |
KR100664400B1 (en) | Composition for preventing the hair from falling out | |
CN112773748A (en) | Traditional Chinese medicine shampoo for treating seborrheic alopecia and application thereof | |
CN109939061B (en) | Safe and non-irritant white hair blackening essence and preparation method thereof | |
CN115006336B (en) | Plant shampoo capable of preventing hair loss, strengthening hair, removing dandruff and relieving itching and preparation method thereof | |
CN113768803B (en) | Composition of anti-hair loss and anti-dandruff spray and preparation method thereof | |
CN113230163B (en) | Application of hydrolyzed yeast protein and chicory root extract in preparation of hair growth and hair nourishing products | |
CN110812310B (en) | Deer fetus extract and composition for preventing alopecia, nourishing and growing hair, and preparation method and application thereof | |
CN112569169A (en) | White-to-black essence | |
KR101048939B1 (en) | Method for producing product for promoting hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210601 |
|
RJ01 | Rejection of invention patent application after publication |